Clinical Trial Update: A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating HLX22 in combination with trastuzumab and chemotherapy for gastroesophageal junction and gastric cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• HLX22
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Gastroesophageal-junction Cancer, Monoclonal Antibody | Phase 3 | Status: RECRUITING